Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
31.52
-0.04 (-0.13%)
Dec 30, 2025, 10:42 AM EST - Market open
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 36,830 employees as of December 31, 2024. The number of employees decreased by 1,021 or -2.70% compared to the previous year.
Employees
36,830
Change (1Y)
-1,021
Growth (1Y)
-2.70%
Revenue / Employee
$455,498
Profits / Employee
$19,359
Market Cap
36.16B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36,830 | -1,021 | -2.70% |
| Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
| Dec 31, 2022 | 36,826 | -711 | -1.89% |
| Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
| Dec 31, 2020 | 40,216 | 177 | 0.44% |
| Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
| Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
| Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
| Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
| Dec 31, 2015 | 42,888 | -121 | -0.28% |
| Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
| Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
| Dec 31, 2012 | 45,948 | 194 | 0.42% |
| Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
| Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
| Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
| Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
| Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
| Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
| Dec 31, 2005 | 14,698 | 885 | 6.41% |
| Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
| Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
| Dec 31, 2002 | 9,577 | 591 | 6.58% |
| Dec 31, 2001 | 8,986 | 361 | 4.19% |
| Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TEVA News
- 6 days ago - S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive - GlobeNewsWire
- 6 days ago - Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade) - Seeking Alpha
- 11 days ago - Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® - GlobeNewsWire
- 21 days ago - Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults - GlobeNewsWire
- 25 days ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 weeks ago - Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - GlobeNewsWire
- 5 weeks ago - Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December - GlobeNewsWire
- 5 weeks ago - Teva seeks startups to help solve global pharmaceutical challenges - Reuters